

CANADIAN PATENT GRANTED TO OPSENS FOR THE EASYWIRE, A CATHETER DEVICE FOR FFR MEASUREMENT

Quebec City, Quebec, October 17, 2011 – OPSENS Inc. (“Opsens”) (TSXV: OPS) announces that the Canadian Intellectual Property Office has issued a patent for its EasyWire, a medical device for the measurement of Fractional Flow Reserve or (« FFR »).

The granting of this patent is particularly significant to Opsens as it defines the unique character of the EasyWire. It also demonstrates the legitimacy and strength of our intellectual property and reinforces our business plan in the medical sector.

EasyWire patent

Patent number 2,721,282 describes EasyWire as an ECCENTRIC PRESSURE CATHETER WITH GUIDEWIRE COMPATIBILITY for the measure of FFR.

The EasyWire is a miniature catheter that slides over a guide wire, to provide a no-drift, highly accurate and reliable measurement of blood pressure in coronary arteries. EasyWire gives cardiologists the freedom to use their favourite guide wire. With the EasyWire the cardiologist can reach the area under investigation faster and easier than with other products on the market, simplifying the procedure.

Data from an animal study showed that EasyWire is safe, delivers good trackability (ability to advance the device through the arteries to reach lesions), and that the pressure measurements taken during the study were optimal. The EasyWire performed exceptionally well, with benefits believed to answer to some important unmet needs.

FFR is an index of the functional severity of coronary stenoses calculated from pressure measurements taken before and after narrowing of arteries discovered during coronary angiography. FFR measurement is an increasingly popular method used in the treatment of cardiac lesions. The FAME Study, published in 2009, outlined the positive result this cost effective procedure has on patients’ overall outcome.

Opsens is also developing the **OptoWire**, a guide wire instrumented with a fiber optic pressure sensor which is drift free and provides a high-fidelity measurement of blood pressure in coronary arteries. A patent application was filed for the OptoWire which is also providing unique mechanical performance and improved delivery capabilities.

Departure of a Director

Opsens announces the resignation of Mr. Gordon Zive as a director of the Corporation. This resignation takes effect immediately.

The entire Board would like to thank Mr. Zive for his contribution and commitment to the Company. His expertise and experience was an appreciated contribution to the Board. We wish him all the best for the future.

About Opsens (www.opsens.com)

Opsens is a leading developer, manufacturer and supplier of a wide range of fiber optic sensors and associated signal conditioners based on proprietary patented and patent pending technologies. Opsens’ sensors provide long-term accuracy and reliability in the harshest environments. Opsens provides sensors to measure pressure, temperature, strain and displacement to original equipment manufacturers (OEM) and end-users in the oil and gas,

medical and laboratory fields. Opsens provides complete technical support, including installation, training, after-sales service, for its fiber optics systems that are regulated by the ISO 9001-2008 and ISO 13485 norms.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

-30-

For further information, please contact:

Pierre Carrier, President and Chief Executive Officer, 418.682.9996

Louis Laflamme, CA, Chief Financial Officer, 418.682.9996